Table 3.

Comparison between group C (split-dose regimen) and group D (thiopurine-allopurinol cotherapy) at 6 and 12 months

Variables	Group C: SDT, n = 29	Group D: LDTA, n = 31	P value
6 mo
6-TGN (median; IQR)	246.5; 22.7	298.5; 64.8	NS
6-MeMP (median; IQR)	1,153; 214.1	262.5; 192.9	<0.05
6-MeMP/6-TGN ratio (median; IQR)	5; 0.8	1; 1	<0.05
ALT (median; IQR)	15.50; 2.2	21; 6.5	<0.05
WBC (median; IQR)	6.2; 0.4	5.7; 0.5	NS
Neutrophils (median; IQR)	3.55; 0.3	2.85; 0.3	NS
Lymphocytes (median; IQR)	1.5; 0.2	2.3; 0.2	NS
RBC (median; IQR)	4.45; 0.1	4.35; 0.1	NS
MCV (median; IQR)	84; 1.5	85.3; 1.1	NS
PLT (median; IQR)	352.5; 14	295.5; 22.2	<0.05
CRP (median; IQR)	5; 1.4	4.9; 1	NS
ESR (median; IQR)	14.5; 6	7; 6.5	NS
Albumin (median; IQR)	43.5; 0.7	43; 0.8	NS
Calprotectin (median; IQR)	339.5; 162.2	104; 210.2	NS
Cotherapies (n)
Infliximab	12	7	NS
Adalimumab	2	3	NS
5-ASA	5	12	NS
Steroids	0	0	—
12 mo
6-TGN (median; IQR)	318; 32.7	322.5; 76.4	NS
6-MeMP (median; IQR)	854.5; 235.3	187.0; 126.2	<0.05
6-TGN/6-MeMP ratio (median; IQR)	3.50; 0.7	0.5; 0.2	<0.001
ALT (median; IQR)	15; 1.9	22; 1.5	NS
WBC (Median; IQR)	7.25; 0.3	6.90; 0.7	NS
Neutrophils (median; IQR)	4.05; 0.3	3.4; 0.5	NS
Lymphocytes (median; IQR)	2; 0.2	2.2; 0.2	NS
RBC (median; IQR)	4.55; 2.7	4.3; 0.4	NS
MCV (median; IQR)	82.95; 6.2	86.1; 1.3	NS
PLT (median; IQR)	365; 18.8	295; 13.4	NS
CRP (median; IQR)	5; 1.3	5; 0.9	NS
ESR (median; IQR)	11; 5.4	13; 2.4	NS
Albumin (median; IQR)	43; 0.8	43; 0.9	NS
Calprotectin (median; IQR)	378.5; 303.3	332.5; 289.4	NS
Cotherapies (n)
Infliximab	11	7	NS
Adalimumab	2	4	NS
Vedolizumab	1	0	—
5-ASA	6	10	NS
Steroids	0	1	—

SDT, split-dose thiopurine; LDTA, low-dose azathioprine-allopurinol cotherapy; 6-TGN, 6-thioguanine nucleotide; 6-MeMP, 6-methyl mercaptopurine; ALT; alanine aminotransferase; WBC, white blood cell; RBC, red blood cell; MCV, mean corpuscular volume; PLT, platelet count; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.